NEW YORK (
CHANGE IN RATINGS
was initiated with a neutral rating at Goldman Sachs. $23 price target. Attractive business but facing several challenges.
was upgraded from market perform to outperform at BMO Capital Markets. $25 price target. Valuation call.
was initiated with a buy rating at Brean Murray. $37 price target. Stregnth of orphan drug, Cinryze.
WBC was upgraded to overweight at JPMorgan. Unique buying opportunity.
STOCK COMMENTS / EPS CHANGES
estimates lowered through 2011, Morgan Stanley said. Should retain defensive appeal despite headwinds. Overweight rating and $13 price target.
numbers raised at Jefferies. Shares of ATU now seen reaching $31, Jefferies said. High-quality first quarter and beat. Buy rating.
Bed Bath & Beyond
estimates increased through 2013, UBS said. Solid results and margin expansion. Maintain $64 price target and neutral rating.
target raised at Goldman Sachs. Shares of CVS now seen reaching $44, Goldman Sachs said. Revived credibility yields confidence in growth algorithm. Buy rating.
numbers lowered at UBS. Shares of EMR now seen reaching $50, according to UBS. Estimates also lowered on climate weakness and flat year-over-year orders. Neutral rating.
2012 Stock Predictions and Outlook
Emerson Electric numbers cut at Citigroup. Shares of EMR now seen reaching $56, according to Citigroup. Estimates also lowered on Thai flood, destocking, and pockets of lower demand. Buy rating.
Emerson Electric target lowered at Goldman Sachs. Shares of EMR now seen reaching $51, Goldman Sachs said. Facing incremental demand weakness. Buy rating.
numbers lowered Goldman Sachs. Shares of KMX now seen reaching $29, Goldman Sachs said. Estimates also lowered on softer same-store unit trends. Neutral rating.
CarMax estimates, target cut at Deutsche Bank. Shares of KMX now seen reaching $31, according to Deutsche Bank. Estimates also lowered as company missed volume and profit expectations.
numbers cut at UBS. Shares of MU now seen reaching $12, according to UBS. Estimates also lowered on DRAM margin erosion. Buy rating.
Micron technology estimates lowered through 2013, Sterne Agee said. Guided NANA-DRAM outlook down. $11 price target and buy rating.
estimates, target lowered at Citigroup. Shares of NFLX now seen reaching $80, according to Citigroup. Estimates also lowered on segment rebuild and disclosure about 2012 losses. Neutral rating.
The Shaw Group
target raised at Goldman Sachs. Shares of SHAW now seen reaching $27, Goldman Sachs said. Improved execution, awards and catalysts prop shares near-term. Neutral rating.
estimates lowered at Guggenheim through 2012. No last ditch settlement with ESRX. Maintain $39 price target and buy rating.
Walgreen Company numbers lowered at Goldman Sachs. Shares of WAG now seen reaching $38, Goldman Sachs said. Estimates also lowered on poor quarter report. Buy rating.
>To submit a news tip, email:
and become a fan on
This article was written by a staff member of RealMoney.com.